Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Opdivo nivolumab: Phase III data

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Opdivo nivolumab (ONO-4538, MDX-1106, BMS-936558) Business: Cancer Molecular target: Programmed cell …

    Published on 7/27/2015
  • Optina danazol: Phase IIb data

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Englewood, Colo. Product: Optina danazol Business: Ophthalmic Molecular target: NA Description: Ultra-low dose formulation of danazol, a derivative of the synthetic steroid …

    Published on 7/27/2015
  • Oral ANAVEX 2-73: Interim Phase IIa data

    Anavex Life Sciences Corp. (OTCQX:AVXL), New York, N.Y. Product: Oral ANAVEX 2-73 Business: Neurology Molecular target: Sigma-1 receptor; Muscarinic receptor Description: Aminotetrahydrofuran derivative agonist of sigma…

    Published on 7/27/2015
  • Oxycodone extended-release: Clinical trial data

    Collegium Pharmaceutical Inc. (NASDAQ:COLL), Canton, Mass. Product: Oxycodone extended-release (Xtampza ER) Business: Neurology Molecular target: Opioid receptor (OPR) Description: Extended-release oral oxycodone …

    Published on 7/27/2015
  • Pexastimogene devacirepvec: Additional Phase Ib data

    Lees Pharmaceutical Holdings Ltd. (HKSE:0950), Hong Kong, China SillaJen Inc., Busan, South Korea Transgene S.A. (Euronext:TNG), Illkirch, France Green Cross Corp. (KSE:006280), Yongin-si, South Korea Product: …

    Published on 7/27/2015
  • RG6013: Additional Phase I/II data

    Genentech Inc., South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: RG6013, ACE910 Business: Hematology Molecular target: …

    Published on 7/27/2015
  • Selumetinib: Phase III data

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Selumetinib (ARRY-886, AZD6244) Business: Cancer Molecular target: MEK Description: Small molecule MEK …

    Published on 7/27/2015
  • Solanezumab: Phase III data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Solanezumab (LY2062430) Business: Neurology Molecular target: Beta amyloid Description: mAb that binds to soluble beta amyloid Indication: Treat mild Alzheimers …

    Published on 7/27/2015
  • Talimogene laherparepvec: Phase Ib/II data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Product: Talimogene laherparepvec (T-VEC) (formerly OncoVEX GM-CSF) Business: Cancer Molecular target: NA Description: Modified herpes simplex virus type 1 (HSV-1) …

    Published on 7/27/2015
  • Tenapanor: Additional Phase IIb data

    Ardelyx Inc. (NASDAQ:ARDX), Fremont, Calif. Product: Tenapanor (AZD1722, RDX5791) Business: Gastrointestinal Molecular target: Solute carrier family 9 sodium hydrogen exchanger member 3 (SLC9A3) (NHE3) Description: …

    Published on 7/27/2015
  • Tosedostat: Phase II final data

    CTI BioPharma Corp. (NASDAQ:CTIC; Milan:CTIC), Seattle, Wash. Vernalis plc (LSE:VER), Winnersh, U.K. Product: Tosedostat (CHR2797) (formerly CHR-2797) Business: Cancer Molecular target: NA Description: Aminopeptidase …

    Published on 7/27/2015
  • AKB-9778: Phase IIa data

    Aerpio Therapeutics Inc., Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Protein tyrosine phosphatase receptor type D (PTPRD) (HPTP) beta Description: Tyrosine kinase receptor 2 (Tie2) …

    Published on 7/20/2015
  • Aldoxorubicin: Additional Phase II data

    CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. Product: Aldoxorubicin (formerly DOXO-EMCH, INNO-206) Business: Cancer Molecular target: DNA Description: 6-maleimidocaproyl hydrazone prodrug of doxorubicin Indication: …

    Published on 7/20/2015
  • ALT-801: Phase Ib/II data

    Altor BioScience Corp., Miramar, Fla. Product: ALT-801, TCR-IL-2 Business: Cancer Molecular target: p53 Description: Soluble tumor antigen-specific T cell receptor (TCR) linked to IL-2 Indication: Treat muscle invasive …

    Published on 7/20/2015
  • Atezolizumab: Phase II data

    Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Atezolizumab (Anti-PDL1) (MPDL3280A, RG7446) Business: Cancer Molecular target: Programmed cell death 1 ligand 1 (PD-…

    Published on 7/20/2015
  • AVX-001: Phase I/IIa data

    Avexxin A/S, Trondheim, Norway Product: AVX-001 Business: Autoimmune Molecular target: Phospholipase A2 group IVA cytosolic calcium-dependent (PLA2G4A) (cPLA2-alpha) Description: Small molecule targeting the …

    Published on 7/20/2015
  • AZD9291: Preliminary Phase Ib data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: AZD9291 Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR) Description: Oral irreversible inhibitor of EGFR-activating mutations and the…

    Published on 7/20/2015
  • Baricitinib: Additional Phase III data

    Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Baricitinib (LY3009104) (formerly INCB28050) Business: Autoimmune Molecular target: Janus kinase-2 (JAK-2); Janus …

    Published on 7/20/2015
  • Baricitinib: Additional Phase III data

    Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Baricitinib (LY3009104) (formerly INCB28050) Business: Autoimmune Molecular target: Janus kinase-2 (JAK-2); Janus …

    Published on 7/20/2015
  • Cimzia certolizumab pegol: Phase III data

    NewBridge Pharmaceuticals Ltd., Dubai, UAE UCB Group (Euronext:UCB), Brussels, Belgium Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Cimzia certolizumab pegol Business: Autoimmune Molecular target: Tumor …

    Published on 7/20/2015
  • Clonidine Lauriad: Phase II final data

    Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, France Product: Clonidine Lauriad (Validive) (BA-028) Business: Other Molecular target: Adrenergic receptor alpha 2 (ADRA2) Description: Mucoadhesive formulation of …

    Published on 7/20/2015
  • Cometriq cabozantinib: Additional Phase II data

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Product: Cometriq cabozantinib (XL184) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1); c-Met …

    Published on 7/20/2015
  • Cometriq cabozantinib: Phase II data

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Product: Cometriq cabozantinib (XL184) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1); c-Met …

    Published on 7/20/2015
  • Crisaborole: Phase III data

    Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), Palo Alto, Calif. Product: Crisaborole (AN2728) Business: Dermatology Molecular target: Phosphodiesterase-4 (PDE-4); Tumor necrosis factor (TNF) alpha Description: Topical …

    Published on 7/20/2015
  • Crisaborole: Phase III data

    Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), Palo Alto, Calif. Product: Crisaborole (AN2728) Business: Dermatology Molecular target: Phosphodiesterase-4 (PDE-4); Tumor necrosis factor (TNF) alpha Description: Topical …

    Published on 7/20/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993